Aligos Therapeutics (NASDAQ:ALGS) Rating Increased to Strong-Buy at Jefferies Financial Group

Jefferies Financial Group upgraded shares of Aligos Therapeutics (NASDAQ:ALGS) to a strong-buy rating in a research report released on Thursday morning,Zacks.com reports.

Other equities analysts also recently issued reports about the company. HC Wainwright reiterated a “buy” rating and set a $50.00 price objective on shares of Aligos Therapeutics in a research report on Wednesday, March 11th. UBS Group began coverage on Aligos Therapeutics in a research report on Wednesday, January 7th. They issued a “buy” rating and a $20.00 target price on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Aligos Therapeutics in a research report on Wednesday, January 21st. Wall Street Zen cut Aligos Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, March 7th. Finally, Westpark Capital started coverage on Aligos Therapeutics in a report on Thursday. They set a “buy” rating and a $48.00 price target on the stock. One equities research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $41.50.

Aligos Therapeutics Stock Up 1.1%

Shares of NASDAQ:ALGS opened at $7.04 on Thursday. The company’s 50-day moving average price is $7.33 and its 200 day moving average price is $8.76. The company has a market cap of $43.56 million, a PE ratio of -0.82 and a beta of 2.67. Aligos Therapeutics has a fifty-two week low of $3.76 and a fifty-two week high of $13.69.

Aligos Therapeutics (NASDAQ:ALGS) last posted its earnings results on Thursday, March 5th. The company reported ($1.91) EPS for the quarter, topping the consensus estimate of ($2.09) by $0.18. Aligos Therapeutics had a negative net margin of 1,106.72% and a negative return on equity of 28.16%. The firm had revenue of $0.17 million during the quarter, compared to analysts’ expectations of $0.27 million. As a group, equities analysts anticipate that Aligos Therapeutics will post -10.36 EPS for the current year.

Institutional Investors Weigh In On Aligos Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the business. NorthCrest Asset Manangement LLC acquired a new stake in Aligos Therapeutics in the 3rd quarter valued at about $98,000. Rockefeller Capital Management L.P. raised its holdings in shares of Aligos Therapeutics by 900.0% in the 4th quarter. Rockefeller Capital Management L.P. now owns 10,000 shares of the company’s stock worth $93,000 after purchasing an additional 9,000 shares in the last quarter. Susquehanna International Group LLP bought a new stake in shares of Aligos Therapeutics in the 3rd quarter worth approximately $99,000. HRT Financial LP acquired a new stake in Aligos Therapeutics during the fourth quarter valued at approximately $106,000. Finally, DRW Securities LLC bought a new stake in Aligos Therapeutics during the fourth quarter worth approximately $111,000. 60.43% of the stock is currently owned by institutional investors.

About Aligos Therapeutics

Aligos Therapeutics, Inc is a clinical‐stage biopharmaceutical company dedicated to the discovery and development of novel therapeutics for chronic viral infections. The company leverages proprietary nucleic acid chemistry and small‐molecule discovery platforms to create therapies aimed at reducing viral replication, lowering antigen levels and restoring host immune function. Its pipeline includes both oligonucleotide conjugates and orally administered small molecules designed to address the root causes of persistent infections.

Founded in 2014 and headquartered in South San Francisco, California, Aligos advances its programs through strategic collaborations with academic institutions, research hospitals and industry partners.